Cerebrovascular disorders and Fabry disease

Abstract

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene encoding for alpha-galactosidase A. Renal, cardiac, and cerebrovascular involvement are the leading complications in early adulthood and are associated with severe morbidity and mortality. Cerebrovascular manifestations in FD manifest as ischemic stroke and transient ischemic attack and less frequently as hemorrhagic strokes. Many patients may develop their stroke not only before other major complications but also before the diagnosis of FD is made. This review will describe the frequency and characteristics of cerebrovascular disease in FD, the complex pathophysiological mechanisms, the neuroimaging findings, the value of screening studies in young patients with stroke, and the controversies regarding the beneficial effect of ERT for the prevention of cerebrovascular disease in FD.

Keywords

Fabry disease / cerebrovascular disorders / ischemic stroke / hemorrhagic stroke / transient ischemic attack

References

[1] Mehta A,Eyskens F.Fabry disease: a review of current management strategies.QJM2010;103:641-59

[2] Germain DP.Fabry disease.Orphanet J Rare Dis2010;5:30 PMCID:PMC3009617

[3] Mehta A,Widmer U.Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.Eur J Clin Invest2004;34:236-42

[4] AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales). [Evaluation of patients with Fabry disease in Argentina].Medicina2010;70:37-43. (in Spanish)

[5] Giugliani R,Ramaswami U.A 15-year perspective of the fabry outcome survey.J Inborn Errors Metab Screen2016;4:e160041

[6] Spada M,Yasuda M.High incidence of later-onset fabry disease revealed by newborn screening.Am J Hum Genet2006;79:31-40 PMCID:PMC1474133

[7] Lin HY,Hsu JH.High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.Circ Cardiovasc Genet2009;2:450-6

[8] Marchesoni CL,Pardal AM.Misdiagnosis in Fabry disease.J Pediatr2010;156:828-31

[9] Reisin R,García-Pavía P.Time delays in the diagnosis and treatment of Fabry disease.Int J Clin Pract2017;71:e12914

[10] von Scheidt W,Fitzmaurice TF.An atypical variant of Fabry’s disease with manifestations confined to the myocardium.N Engl J Med1991;324:395-9

[11] Nakao S,Takenaka T.Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype.Kidney Int2003;64:801-7

[12] Rolfs A,Grittner U.Stroke in Young Fabry Patients (sifap) InvestigatorsAcute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study.Stroke2013;44:340-9

[13] Wanner C,Baron R.European expert consensus statement on therapeutic goals in Fabry disease.Mol Genet Metab2018;124:189-203

[14] Schiffmann R,Austin HA 3rd.Enzyme replacement therapy in Fabry disease: a randomized controlled trial.JAMA2001;285:2743-9

[15] Eng CM,Wilcox WR.International Collaborative Fabry Disease Study GroupSafety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease.N Engl J Med2001;345:9-16

[16] Germain DP,Nicholls K.Treatment of Fabry’s disease with the pharmacologic chaperone migalastat.N Engl J Med2016;375:545-55

[17] Schiffmann R.Fabry disease.Pharmacol Ther2009;122:65-77

[18] Moore DF,Askari H.The cerebral vasculopathy of Fabry disease.J Neurol Sci2007;257:258-63

[19] Joly DA.3-Nitrotyrosine as a biomarker for vascular involvement in Fabry disease.Kidney Int2014;86:5-7

[20] Shu L,Pennathur S.Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.Kidney Int2014;86:58-66 PMCID:PMC4077934

[21] Hilz MJ,Brys M,Haendl T.Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.J Neurol2004;251:564-70

[22] Moore DF,Ling GSF.Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.Stroke2002;33:525-31

[23] Biancini GB,Rodrigues DB.Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.Biochim Biophys Acta2012;1822:226-32

[24] Simoncini C,Montano V.Oxidative stress biomarkers in Fabry disease: is there a room for them?.J Neurol2020;267:3741-52 PMCID:PMC7674365

[25] Rozenfeld P.Contribution of inflammatory pathways to Fabry disease pathogenesis.Mol Genet Metab2017;122:19-27

[26] Spada FM,Porcelli SA.CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells.J Exp Med1998;188:1529-34 PMCID:PMC2213414

[27] Gumperz JE,Yamamura T.Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining.J Exp Med2002;195:625-36 PMCID:PMC2193772

[28] O’Reilly V,Bricard G.Distinct and overlapping effector functions of expanded human CD4⁺, CD8α⁺ and CD4^-CD8α^- invariant natural killer T cells.PLoS One2011;6:e28648 PMCID:PMC3236218

[29] Reisin RC,Bonardo P.Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis.Med Hypotheses2020;144:110282 PMCID:PMC7494494

[30] Schiffmann R.Fabry disease.Handb Clin Neurol2015;132:231-48

[31] Biancini GB,Hammerschmidt T.Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy.Clin Chim Acta2016;461:41-6

[32] Kang JJ,Desch KC.α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.Kidney Int2019;95:149-59 PMCID:PMC6320285

[33] DeGraba T,Dignat-George F.Profile of endothelial and leukocyte activation in Fabry patients.Ann Neurol2000;47:229-33

[34] Shen JS,Moore DF.Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.Mol Genet Metab2008;95:163-8 PMCID:PMC2593623

[35] Park S,Joo KY.Globotriaosylceramide leads to K_Ca3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.Cardiovasc Res2011;89:290-9

[36] Choi S,Na HY.Globotriaosylceramide induces lysosomal degradation of endothelial K_Ca3.1 in fabry disease.Arterioscler Thromb Vasc Biol2014;34:81-9

[37] Aerts JM,Kuiper S.Elevated globotriaosylsphingosine is a hallmark of Fabry disease.Proc Natl Acad Sci U S A2008;105:2812-7 PMCID:PMC2268542

[38] Rombach SM,Aerts JM,Wijburg FA.Vasculopathy in patients with Fabry disease: current controversies and research directions.Mol Genet Metab2010;99:99-108

[39] Dandona P,Ghanim H.Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.J Hum Hypertens2007;21:20-7

[40] Cavanagh EM, Ferder M, Inserra F, Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint.Am J Physiol Heart Circ Physiol2009;296:H550-8

[41] Mishra V,Gandhi AB.Stroke and Fabry disease: a review of literature.Cureus2020;12:e12083 PMCID:PMC7805529

[42] Lam YLT,Kwok HM,Ma KFJ.Basilar artery diameter as neuroimaging biomarker in Chinese Fabry disease patients.Orphanet J Rare Dis2023;18:186 PMCID:PMC10334527

[43] Uçeyler N,Guerrero González H.Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease.PLoS One2014;9:e87054 PMCID:PMC3903616

[44] Fellgiebel A,Martus P.Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients.Cerebrovasc Dis2011;31:294-9

[45] Pico F,Touboul PJ,Amarenco P.Intracranial arterial dolichoectasia and small-vessel disease in stroke patients.Ann Neurol2005;57:472-9

[46] Zhang DP,Zhang HL,Song B.Association between intracranial arterial dolichoectasia and cerebral small vessel disease and its underlying mechanisms.J Stroke2020;22:173-84 PMCID:PMC7341005

[47] Mehta A,Giugliani R.FOS InvestigatorsNatural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.J Med Genet2009;46:548-52

[48] Hagège A,Habib G.Fabry disease in cardiology practice: Literature review and expert point of view.Arch Cardiovasc Dis2019;112:278-87

[49] Weidemann F,Beer M.The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.Eur Heart J2005;26:1221-7

[50] Kampmann C,Perrot A,Dietz R.The heart in Anderson Fabry disease.Z Kardiol2002;91:786-95

[51] Weidemann F,Störk S.Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy.Am J Cardiol2016;118:264-74

[52] Beck M.Comment: why are females with Fabry disease affected?.Mol Genet Metab Rep2019;21:100529 PMCID:PMC6819736

[53] Fuller M,Hein LK,Meikle PJ.Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.Mol Genet Metab2015;114:268-73

[54] Dobyns WB,Tomson BN.Inheritance of most X-linked traits is not dominant or recessive, just X-linked.Am J Med Genet A2004;129A:136-43

[55] Kolodny E,Hilz MJ.Cerebrovascular involvement in Fabry disease: current status of knowledge.Stroke2015;46:302-13

[56] Mitsias P.Cerebrovascular complications of Fabry’s disease.Ann Neurol1996;40:8-17

[57] Mehta A. Fabry disease. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1292/. [Last accessed on 21 March 2024]

[58] Morgan SH,Smith SJ.The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency) - investigation of symptomatic and presymptomatic patients.Q J Med1990;75:491-507

[59] Grewal RP.Stroke in Fabry’s disease.J Neurol1994;241:153-6

[60] Buechner S,Burlina AP.Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study.J Neurol Neurosurg Psychiatry2008;79:1249-54

[61] Galanos J,Grigg L,Crawford A.Clinical features of Fabry’s disease in Australian patients.Intern Med J2002;32:575-84

[62] Vedder AC,van Breemen MJ.The Dutch Fabry cohort: diversity of clinical manifestations and Gb₃ levels.J Inherit Metab Dis2007;30:68-78

[63] Utsumi K,Watanabe M.Thrombosis in Japanese patients with Fabry disease.J Neurol Sci2009;283:83-5

[64] MacDermot KD,Miners AH.Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.J Med Genet2001;38:769-75 PMCID:PMC1734754

[65] MacDermot KD,Miners AH.Natural history of Fabry disease in affected males and obligate carrier females.J Inherit Metab Dis2001;24:13-4

[66] Gupta S,Kotsopoulos S.The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.Medicine2005;84:261-8

[67] Mehta A.FOS InvestigatorsNatural history of the cerebrovascular complications of Fabry disease.Acta Paediatr Suppl2005;94:24-7

[68] Ginsberg L.Nervous system manifestations of Fabry disease: data from FOS - the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 23.

[69] Sims K,Banikazemi M.Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.Stroke2009;40:788-94

[70] Vijapurapu R,Demetriades P.Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease.Open Heart2023;10:e002316 PMCID:PMC10357684

[71] Chugh SS,Narayanan K.Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.Circulation2014;129:837-47 PMCID:PMC4151302

[72] Rolfs A,Zschiesche M.Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.Lancet2005;366:1794-6

[73] Shi Q,Pongmoragot J,Saposnik G.Prevalence of Fabry disease in stroke patients - a systematic review and meta-analysis.J Stroke Cerebrovasc Dis2014;23:985-92

[74] Marquardt L,Segal H.Fabry disease in unselected patients with TIA or stroke: population-based study.Eur J Neurol2012;19:1427-32

[75] Reisin RC,Cejas LL.AISYF InvestigatorsPrevalence of Fabry disease in young patients with stroke in Argentina.J Stroke Cerebrovasc Dis2018;27:575-82

[76] Doheny D,Pagant S,Yasuda M.Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017.J Med Genet2018;55:261-8

[77] Härtl J,Wunderlich S.Regeneron Genetics CenterExome-based gene panel analysis in a cohort of acute juvenile ischemic stroke patients:relevance of NOTCH3 and GLA variants.J Neurol2023;270:1501-11 PMCID:PMC9971083

[78] Palaiodimou L,Bakola E.D313Y variant in Fabry disease: a systematic review and meta-analysis.Neurology2022;99:e2188-200

[79] Low M,Tubridy N.Neurology of Fabry disease.Intern Med J2007;37:436-47

[80] Kono Y,Kobayashi M.Characteristics of cerebral microbleeds in patients with Fabry disease.J Stroke Cerebrovasc Dis2016;25:1320-5

[81] Cocozza S,Pontillo G,Brunetti A.Neuroimaging in Fabry disease: current knowledge and future directions.Insights Imaging2018;9:1077-88 PMCID:PMC6269338

[82] Reisin RC,Marchesoni C.Brain MRI findings in patients with Fabry disease.J Neurol Sci2011;305:41-4

[83] Brooks JBB.Neurological manifestations in Fabry disease.Neuroimmunol Neuroinflammation2016;3:228

[84] Fellgiebel A,Mazanek M,Beck M.White matter lesion severity in male and female patients with Fabry disease.Neurology2005;65:600-2

[85] Kaye EM,Logigian EL.Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation.Ann Neurol1988;23:505-9

[86] Marchesoni C,Pfister P.Brain MRI findings in children and adolescents with Fabry disease.J Neurol Sci2018;395:131-4

[87] Shribman SE,Werring DJ.Fabry disease mimicking multiple sclerosis: lessons from two case reports.Mult Scler Relat Disord2015;4:170-5

[88] Rath J,Haider L.Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease.Orphanet J Rare Dis2022;17:37 PMCID:PMC8817613

[89] Cocozza S,Riccio E.Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis.Neuroradiology2017;59:563-70

[90] Böttcher T,Tanislav C.Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?.PLoS One2013;8:e71894 PMCID:PMC3756019

[91] Lyndon D,Wilson D.MRI-visible perivascular spaces as an imaging biomarker in Fabry disease.J Neurol2021;268:872-8 PMCID:PMC7914182

[92] Moore DF,Schiffmann R.Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease.AJNR Am J Neuroradiol2003;24:1096-101 PMCID:PMC8149001

[93] Takanashi J,Dillon WP,Hart KA.T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease.AJNR Am J Neuroradiol2003;24:916-21. PMCID:PMC7975809

[94] Burlina AP,Caillaud C.The pulvinar sign: frequency and clinical correlations in Fabry disease.J Neurol2008;255:738-44

[95] Cocozza S,Pisani A.Redefining the pulvinar sign in Fabry disease.AJNR Am J Neuroradiol2017;38:2264-9 PMCID:PMC7963734

[96] Manara R,Righetto S.Basilar artery changes in Fabry disease.AJNR Am J Neuroradiol2017;38:531-6 PMCID:PMC7960013

[97] Fazekas F, Enzinger C, Schmidt R, et al; SIFAP 1 Investigators. Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event. Stroke 2015;46:1548-53.

[98] Ortiz A,Desnick RJ.Fabry disease revisited: management and treatment recommendations for adult patients.Mol Genet Metab2018;123:416-27

[99] Germain DP,Decramer S.Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients.Clin Genet2019;96:107-17 PMCID:PMC6852597

[100] Pontillo G,Brunetti A.Reduced intracranial volume in Fabry disease: evidence of abnormal neurodevelopment?.Front Neurol2018;9:672 PMCID:PMC6107697

[101] Paavilainen T,Saunavaara J.Diffusion tensor imaging and brain volumetry in Fabry disease patients.Neuroradiology2013;55:551-8

[102] Fellgiebel A,Whybra C.Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study.J Neurol2006;253:780-7

[103] Tedeschi G,Banerjee TK,Schiffmann R.Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study.Neurology1999;52:1663-7

[104] Gabusi I,Petracca M.Structural disconnection and functional reorganization in Fabry disease: a multimodal MRI study.Brain Commun2022;4:fcac187 PMCID:PMC9327118

[105] Elstein D,Altarescu G.Cognitive testing in Fabry disease: pilot using a brief computerized assessment tool.Isr Med Assoc J2012;14:624-8

[106] Segal P,Pollak Y,Galili-Weisstub E.Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study.J Inherit Metab Dis2010;33:429-36

[107] Mendez MF,Medel NM,Tedesco DT.The vascular dementia of Fabry’s disease.Dement Geriatr Cogn Disord1997;8:252-7

[108] Okeda R.An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia.Neuropathology2008;28:532-40

[109] Loeb J,Madsen CV.Cognitive impairments and subjective cognitive complaints in Fabry disease: a nationwide study and review of the literature.JIMD Rep2018;41:73-80 PMCID:PMC6122045

[110] Sigmundsdottir L,Knopman AA,Batchelor J.Cognitive and psychological functioning in Fabry disease.Arch Clin Neuropsychol2014;29:642-50 PMCID:PMC4263929

[111] Körver S,Hollak CEM.Cognitive functioning and depressive symptoms in Fabry disease: a follow-up study.J Inherit Metab Dis2020;43:1070-81 PMCID:PMC7540266

[112] Anderson JF,Srikanth VK,Donnan GA.Individuals with first-ever clinical presentation of a lacunar infarction syndrome: Is there an increased likelihood of developing mild cognitive impairment in the first 12 months after stroke?.J Neuropsychol2008;2:373-85

[113] Lelieveld IM,Hennermann JB,Fellgiebel A.Eight-year follow-up of neuropsychiatric symptoms and brain structural changes in Fabry disease.PLoS One2015;10:e0137603 PMCID:PMC4560446

[114] Löhle M,Milligan A.Clinical prodromes of neurodegeneration in Anderson-Fabry disease.Neurology2015;84:1454-64 PMCID:PMC4390387

[115] Loret G,Vingerhoets G,Hemelsoet D.A long-term neuropsychological evaluation in Fabry disease.Acta Neurol Belg2021;121:191-7

[116] Schermuly I,Müller KM.Neuropsychiatric symptoms and brain structural alterations in Fabry disease.Eur J Neurol2011;18:347-53

[117] Wadley VG,Warnock DG.Cognitive function in adults aging with Fabry disease: a case - control feasibility study using telephone-based assessments.JIMD Rep2015;18:41-50 PMCID:PMC4361921

[118] Cociasu I,Tuttolomondo A.Anderson-Fabry disease: a rare cause of levodopa-responsive early-onset Parkinsonism.Mov Disord Clin Pract2021;8:S32-4 PMCID:PMC8414496

[119] Kahn P.Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain.J Neurol Neurosurg Psychiatry1973;36:1053-62 PMCID:PMC1083608

[120] Zedde M,Cavallieri F.Anderson-Fabry disease: a new piece of the lysosomal puzzle in Parkinson disease?.Biomedicines2022;10:3132 PMCID:PMC9776280

[121] Schiffmann R,Abu-Asab M.Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement.Virchows Arch2006;448:337-43 PMCID:PMC2288734

[122] Ortiz A,Bichet DG.Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.J Med Genet2016;53:495-502 PMCID:PMC4941144

[123] Sheng S,Nalleballe K.Fabry’s disease and stroke: Effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis.J Clin Neurosci2019;65:83-6

[124] Fellgiebel A,Wildberger K,Desnick RJ.Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.Cerebrovasc Dis2014;38:448-56

[125] Rost NS,Kanakis AS.Determinants of white matter hyperintensity burden in patients with Fabry disease.Neurology2016;86:1880-6 PMCID:PMC4873685

[126] Lenders M,Duning T.Thromboembolic events in Fabry disease and the impact of factor V Leiden.Neurology2015;84:1009-16

[127] Ferrari G,Kisinovsky I.Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa.Medicina2021;81:173-9

[128] Eng CM,Banikazemi M.Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.Genet Med2006;8:539-48

[129] Fazekas F,Schmidt R.sifap1 InvestigatorsMRI in acute cerebral ischemia of the young: the Stroke in Young Fabry Patients (sifap1) Study.Neurology2013;81:1914-21

[130] Politei JM.Can we use statins to prevent stroke in Fabry disease?.J Inherit Metab Dis2009;32:481-7